Table 3.
Odds Ratio [(for ADA vs. IFX(ref)] | 95% confidence interval (CI) | |
---|---|---|
Crohn’s disease | ||
Narrative outcomes | ||
Symptomatic non-response score at 1 year | 1.62 | 1.21 – 2.17 |
Codified outcomes | ||
Composite outcome | 1.17 | 0.86 – 1.60 |
Surgery | 1.28 | 0.73 – 2.24 |
Hospitalization | 1.01 | 0.72 – 1.42 |
Prednisone prescription | 1.29 | 0.92 – 1.81 |
Normalization of CRP | 1.13 | 0.72 – 1.78 |
Ulcerative colitis | Odds Ratio [(for ADA vs. IFX(ref)] | 95% CI |
Narrative outcomes | ||
Symptomatic non-response score at 1 year | 1.53 | 0.86 – 2.73 |
Codified outcomes | ||
Composite outcome | 0.72 | 0.40 – 1.29 |
Surgery | 0.99 | 0.43 – 2.25 |
Hospitalization | 1.32 | 0.70 – 2.47 |
Prednisone prescription | 0.66 | 0.36 – 1.20 |
Normalization of CRP | 1.13 | 0.72 – 1.78 |
CRP – C-reactive protein
available for 309 CD patients with IFX; 212 CD patients with ADA; 195 UC patients with IFX, 53 UC patients with ADA
Adjusted for interval between first IBD diagnosis code and anti-TNF start date, gender, prior surgery or hospitalization, prior anti-TNF use, and combination immunomodulator therapy. Additionally adjusted for perianal involvement and penetrating phenotype in CD